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Modulation of mdrl expression by cytokines in human colon carcinoma
cells: an approach for reversal of multidrug resistance
U Stein, W Walther and RH Shoemaker
Laboratory ofDrug Discovery Research and Development, Developmental Therapeutics Program, Division of Cancer Treatment,
National Cancer Institute, Frederick, Maryland 21702-1201, USA.
Summary Reversal of multidrug resistance (MDR) may offer a means of increasing the effectiveness of
tumour chemotherapy. A variety of recent evidence indicates that cytokines may be particularly useful in this
endeavour. To investigate the molecular mechanism by which cytokines may sensitise multidrug-resistant colon
carcinoma cells, HCT15 and HCT116, to treatment with MDR-related drugs, we evaluated the effects of the
human cytokines tumour necrosis factor a (TNFa), interleukin 2 (IL-2) and interferon y (IFN'y) on mdrl gene
expression at the mRNA level by reverse transcription-polymerase chain reaction (RT-PCR) and at the
protein level with monoclonal antibodies by immuno flow cytometry. P-glycoprotein function was examined
after accumulation of the fluorescent drug, doxorubicin, by flow cytometry. Chemosensitivity to doxorubicin
and vincristine was analysed using the XTT assay. All three cytokines were found to modulate the MDR
characteristics on mdrl expression levels, P-glycoprotein function and measured chemosensitivity to MDR-
associated anti-cancer drugs. This cytokine-induced reversal of MDR was strongly time dependent, with
maximal effects after 48 and 72 h of cytokine treatment. If similar modulation of MDR phenotype can be
obtained in in vivo models, it may be possible to verify the time course for modulation by cytokine treatment
and to design appropriate clinical trials of this strategy for MDR reversal.
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Successful chemotherapy of human cancers is often limited
by resistance against structurally and functionally unrelated
drugs (Germann et al., 1993; Roninson, 1991). Multidrug
resistance (MDR) represents a resistance mechanism with
potential clinical relevance, frequently observed in tumours
derived from tissues with excretory/secretory functions like
colon, liver, kidney, etc. (Goldstein et al., 1989; Nooter and
Herweijer, 1991). The MDR phenotype is caused by
overexpression of the mdrl gene encoding the P-glycopro-
tein, which is responsible for the energy-dependent extrusion
of a variety of compounds, resulting in decreased concentra-
tions of, e.g. chemotherapeutic drugs within the cells
(Endicott and Ling, 1989; Valverde et al., 1992; Chin et al.,
1993; Abraham et al., 1993; Roepe, 1995).
For many years, various approaches to reversal of MDR
in human tumour cells have been investigated. A variety of
compounds are able to modulate MDR phenotype. Sub-
stances belonging to this group include calcium channel
antagonists, cyclosporin, calmodulin inhibitors, antimalarials
and steroids (Lum et al., 1993; Raderer and Scheithauer,
1993). Their effects on MDR reversal have been analysed by
functional assays of P-glycoprotein, such as altered anti-
cancer drug efflux and accumulation of fluorescent dyes, as
well as through drug resistance assays. Although these
compounds were examined in phase I/II trials showing
activity in some cancers (Lum et al., 1993), their clinical
activity, as well as their mode of action for MDR reversal,
remains controversial (Wadkins and Houghton, 1993;
McLeod, 1994).
Other strategies to overcome MDR include alteration of
mdrl gene expression by antisense oligonucleotides, inhibition
of P-glycoprotein function with antibodies, selection of
cytotoxic drugs unaffected by P-glycoprotein, reduction of
the availability of ATP, regional administration of modula-
tors, or liposomal encapsulation of cytotoxic agents, as
reviewed by Kellen (1993). Most of these approaches are
focused on modulation of P-glycoprotein function.
An alternative strategy for an efficient MDR reversal
concerns the regulation of mdrl gene expression. Since it has
been shown that tumour response rates may increase when
treatment with conventional chemotherapeutic drugs is
combined with cytokines (Wadler and Schwartz, 1990),
several cytokines were analysed for their capability to
influence the MDR phenotype, and specifically, to modulate
mdrl expression. So far, there are reports examining MDR
modulation effects for TNF (Salmon et al., 1989; Kikuchi et
al., 1992; Walther and Stein, 1994; Borsellino et al., 1994),
IFN a (Scala et al., 1991; Kikuchi et al., 1992; Kang and
Perry, 1994; Fogler et al., 1995), IFN y (Kikuchi et al., 1992;
Walther and Stein, 1994), IL-i a (Borsellino et al., 1994;
Monti et al., 1994), IL-2 (Walther and Stein, 1994) as well as
for leukoregulin (Evans and Baker, 1992), representing
cytokines with different modes of action. Thus, it appears
that cytokines are able to influence/overcome MDR
phenotype and to enhance cytotoxicity of MDR-associated
drugs to tumour cells. In most studies this has been shown by
comparison of parental cells and resistant sublines. However,
data obtained for cytokine-induced mdrl expression modula-
tion on mRNA and/or protein level, have not been
consistently described (Salmon et al., 1989; Scala et al.,
1991; Evans and Baker, 1992; Walther and Stein, 1994; Kang
and Perry, 1994).
The present report provides a detailed investigation of the
dependence on time and on cell line's MDR phenotype of
cytokine-mediated effects on mdrl expression and chemosen-
sitivity in cytokine-pretreated cells. The study presents new
data, which may be important in planning improved
combination therapy approaches for treatment of drug-
resistant tumours. The capability of the cytokines, TNFa,
IL-2 and IFNy, to modulate/reverse the MDR phenotype
was investigated. Our interest was focused on two human
colon carcinoma cell lines, HCT15 and HCT116, which
express different levels of mdrl mRNA/P-glycoprotein and,
therefore, possess different P-glycoprotein-mediated MDR
phenotypes. Cells of both lines were incubated with
100 U ml-' TNFa, IL-2 or IFNy for 2, 12, 24, 48 and 72 h
respectively. Cytokine-induced effects were examined on the
mdrl mRNA level by reverse transcription-polymerase chain
reaction (RT-PCR), on the P-glycoprotein level with
monoclonal antibodies by immuno flow cytometry, on the
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using a fluorescent drug, as well as by chemosensitivity assays
with MDR-associated drugs. The following questions were
addressed: (1) Do these cytokines modulate/decrease mdrl
expression on mRNA and/or P-glycoprotein level? (2) Do
they influence P-glycoprotein function? (3) Do they cause
enhanced cytotoxicity of MDR-associated drugs, like
doxorubicin and vincristine? (4) Do they act in a time-
dependent manner? and finally, (5) Do they modulate mdrl
expression and/or MDR phenotype in dependence on the cell
line's MDR rank?
Materials and methods
Cell lines
The human colon carcinoma cell lines, HCT15 (Iwahashi et
al., 1991) and HCT1 16 (Brattain et al., 1981), were selected
from the 62 cell line panel of the National Cancer Institute,
USA, which is extensively used for screening assays of new
anti-cancer drugs. These cell lines are well characterised,
including their properties of resistance phenotypes as well as
their expression levels of resistance-associated genes like mdrl
(Wu et al., 1992; Izquierdo et al., 1996). Therefore, both cell
lines possess the P-glycoprotein-mediated type of MDR
intrinsically, with the higher MDR rank for HCT15
compared with HCT116.
Cells were grown in RPMI-1640 medium supplemented with
10% fetal calf serum (FCS; Hy Clone, Logan, UT, USA) and
5 mM L-glutamine at 37°C and 5% carbon dioxide.
Cytokine treatment
To analyse the influence of cytokines on mdrl expression,
1 x 105 colon carcinoma cells were seeded into each well of
24-well dishes (Costar, Cambridge, MA, USA) and were
cultured for 12 h in 1 ml medium. To test cytokine sensitivity
in HCT15 and HCT1 16 cells, concentrations of 10 U ml-',
100 U ml-' and 1000 U ml-' of TNF, IL-2 and IFN 'y were
tested for 2, 12, 24, 48 and 72 h. Both cell lines did not show
antiproliferative or cytotoxic response to either cytokine at 10
or 100 U ml-'; however, 1000 U ml-' of TNF, IL-2 or IFN
7 caused significant growth-inhibitory effects, indicating that
the latter concentrations could not be used for the study.
Furthermore, since earlier experiments have shown that
100 U ml-' of TNF, IL-2 or IFN y are suitable for
combination experiments with cytostatic drugs, cytokine
concentrations of 100 U ml-' were applied for all experi-
ments in this study. Cells were treated with the recombinant
cytokines TNF, IL-2 and IFN'y (Promega, Madison, WI,
USA) at 37'C. After 2, 12, 24, 48 and 72 h, cytokine-
containing medium was removed and cells were used either
for RNA isolation, P-glycoprotein detection by MRK16 or
C219 or doxorubicin accumulation experiments.
RNA isolation and RT-PCR
After washing the cells with 1 ml ice-cold 0.9% sodium
chloride solution, they were harvested by addition of 200 pl
lithium chloride/urea (3 M lithium chloride, 6 M urea; Sigma,
St Louis, MO, USA). Total RNA was prepared using the
miniprep-RNA protocol (Walther et al., 1994). RT-PCR
was performed with the Gene Amp RNA PCR kit (Perkin
Elmer via Roche Molecular Systems Inc., Branchburg, NJ,
USA). The RT reaction was performed using 1 pg of each
miniprep-RNA with the random hexamer primers supplied
with the kit. PCR was carried out using mdrl-specific primers
(Noonan et al., 1990) producing a 167 bp product, or fl-actin-
specific primers (Wu et al., 1992) producing a 316 bp
product. Steps for RT were as follows: the RT reaction was
run at 42°C for 15 min, followed by an RT-inactivating
denaturation step at 95°C for 5 min and a cooling step at 5°C
for 5 min. Amplification was performed initially at 95°C for
2 min, continued for 35 cycles of melting (950C for 1 min)
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and annealing-extending with Taq thermostable polymerase
(60°C for 1 min), followed by a final step at 72°C for 7 min.
Gel electrophoresis for separation of RT-PCR products was
performed in a 1.5% agarose gel and was semiquantitated
from video images by densitometry using the Image 1.37
program (obtained from Wayne Rasband, NIMH, Bethesda,
MD, USA). To ensure the results, the same cell lines were
treated several times with the cytokines in separate
experiments to perform RT-PCR. Moreover, several RT-
PCRs from the same RNA sample were carried out.
P-glycoprotein detection by MRK16 and C219 immunoflow
cytometry
HCT15 and HCT116 cells were trypsinised and harvested in
phosphate-buffered saline (PBS; w/o Ca2" and Mg2+). The
monoclonal antibody C219 (Signet Laboratories Inc.,
Dedham, MA, USA) recognises an intracytoplasmic epi-
tope. Therefore, cells were permeabilised by incubation in
3.7% formaldehyde for 10 min at room temperature and
washed once with PBS. All cells were resuspended in 2%
heat-inactivated human AB serum (Irvine Scientific, Santa
Ana, CA, USA) for 5 min at room temperature to prevent
non-specific antibody binding. After washing, the cells were
incubated at 4°C with the appropriate monoclonal antibody
in a PBS solution containing 2% bovine serum albumin
(BSA): 2 pg of C219/5 x 105 cells for 60 min, or in a 1:100
dilution of MRK16 (Hoechst Japan Ltd., Japan), which
recognises an external epitope of P-glycoprotein, for 30 min.
Cells incubated with the mouse IgG, (Becton Dickinson
Immunocytometry Systems, San Jose, CA, USA) served as
negative controls. A fluorescein-conjugated goat anti-mouse
antibody (Tago Inc., Burlingham, CA, USA) was used as a
secondary antibody and cells were treated for 30 min at 4°C.
After washing, the fluorescence intensity of 1 x 104 cells per
group was measured with a FACScan flow cytometer (Becton
Dickinson, Mountain View, CA, USA). Quantitation of the
data was done by using the LYSYS software program, which
enables the calculation and the statistics of each of the entire,
non-gated histograms.
Doxorubicin accumulation
Accumulation of the fluorescent anthracycline doxorubicin
(Sigma, St Louis, MO, USA) was measured as a functional
index of P-glycoprotein activity. For these studies, cells were
cultured in phenol red-free RPMI-1640, supplemented with
10% FCS. They were trypsinised and washed with phenol
red-free RPMI-1640/5% FCS, aliquoted and incubated for
3 h at 37°C in phenol red-free RPMI-1640/5% FCS
containing 50 gM doxorubicin (Leonce et al., 1992). After
incubation, cells were washed twice with medium and held on
ice. Fluorescence intensity of 1 x 104 cells was then
determined by flow cytometry for each treatment group. As
a necessary prerequisite, series of time course experiments for
doxorubicin accumulation were performed after 30 min, 1 h,
2 h, 3 h and 5 h in both cell lines, which was the basis for the
following 3 h drug accumulation experiments. After 5 h of
doxorubicin incubation, a plateau was reached in both lines.
Drug incubation time:
Mean fluorescence
per cell in HCT15:
Mean fluorescence
per cell in HCT116:
0 30min Ih 2h 3h 5h
2.8 5.9 11.8 23.8 32.2 44.8
3.9 20.3 54.9 141.4 205.4 234.6
Chemosensitivity assay
Chemosensitivity of tumour cell lines was determined by
using the XTT (2,3-bis(2-methoxy-4-nitro-5-sulphophenyl)-5-
((phenylamino)carbonyl)-2H-tetrazolium hydroxide) cytotoxi-
city assay (Scudiero et al., 1988). One hundred cells were
plated into each well of 96-well microtitre plates (Costar,
Cambridge, MA, USA), grown for 12 h and incubated withCytokine mediated reversal of MDR W0 U Stein et at
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the appropriate cytokine at a concentration of 100 U ml-1
for 2, 12, 24, 48 and 72 h at 37°C. The cytokine-containing
medium was then removed, 200 ,l dilutions of the
appropriate drug were added (doxorubicin: 50-2000 ng
ml-; vincristine: 50-1500 ng ml-') and incubation was
continued for 3 days at 37°C. After incubation, medium
was removed and 50 ,l XTT solution (1 mg ml-I XTT in
serum-free medium and 0.02 mM N-methylphenazonium
methosulphate) per well was added for 4 h at 37°C. Cells
treated only with drugs for 3 days or treated simultaneously
with cytokines and drugs for 3 days served as controls. In
separate experiments, the IC50 for doxorubicin or vincristine
in cytokine-treated and -untreated tumour cells was
determined and the dose-modifying factor was calculated
(Table 1). Absorbance was measured at 450 nm in a
microplate reader. Absorbance of untreated controls was
taken as 100% survival and the percentage inhibition was
calculated as follows:
Growth inhibition (%) = - (U
- B)
where T, treated: absorbance determined when tumour cells
are exposed to drugs; U, untreated: absorbance of untreated
cells; B, blank: absorbance when neither the drug nor XTT
was added.
cytokine used. After 48 h of treatment with TNF, IL-2 or
IFN'y, a decrease of mdrl mRNA level was detected in the
highly resistant HCT15 as well as in the HCT116 line,
compared with the untreated controls. Although the
a
1 2 3 4 5 6 7 8 9 101112 13 1415 16 1718
- mdrl
-- -actin
Statistical analysis
The levels of statistical significance were evaluated with data
from at least three independent experiments using Student's t-
test.
Results
mdrl gene expression in cytokine-treated cells
Expression of the mdrl gene was evaluated in human colon
carcinoma cell lines HCT15 and HCT116 by RT-PCR.
Total RNA was isolated and mdrl expression was determined
using mdrl-specific primers producing a 167 bp RT-PCR
product. Control RT-PCR was carried out in parallel with
fl-actin-specific primers producing a 316 bp RT-PCR
product. RNA from untreated parental cells served as
controls. RT -PCR for the untreated cells of both lines
(always in the stage of subconfluence) at the time points of 2,
12, 24, 48 and 72 h resulted in unchanged mdrl expregsion
levels. Products were determined by video densitometry in a
semiquantitative analysis and calculated as relative mdrl
expression (mdrl expression/fl-actin expression).
To examine the influence of several cytokines on mdrl
expression, HCT15 and HCT116 cells were incubated with
100 U ml-' of TNF, IL-2 or IFNy for 2, 12, 24, 48 and 72 h.
As shown in Figure 1, mdrl-specific products were detectable
at each time point during cytokine treatment. It was observed
that the mdrl expression level in cytokine-treated cells was
modulated in a time-dependent manner regardless of the
b
1 2 3 4 5 6 7 8 9 1011 12 13 1415 161718
mdrl
- -actin
Figure 1 RT-PCR analysis of mdrl mRNA expression in
cytokine-pretreated human colon carcinoma cells. a, HCT 15; b,
HCT 116; lane 1, DNA molecular weight marker VI (Boehringer
Mannheim, Germany); lane 2, standard DNA 460bp; lane 3,
parental, untreated cells; lanes 4-8, TNF pretreatment for 2, 12,
24, 48 and 72h; lanes 9-14, IL-2 pretreatment for 2, 12, 24, 48
and 72h; lanes 15-19, IFNy pretreatment for 2, 12, 24, 48 and
72h. The sizes for the specific RT-PCR products are 167bp for
mdrl and 316bp for ,B-actin. Results were confirmed by at least
three independent cytokine treatment experiments.
Table I Enhancement of chemosensitivity of doxorubicin and vincristine in simultaneously (cytokine and MDR-associated drug) or cytokine-
pretreated human HCT15 and HCT116 colon carcinoma cells
DMF'for doxorubicin DMFfor vincristine
Cytokine pretreatment (h) Cytokine pretreatment (h) Cell line Cytokine Simultaneous 2 12 24 48 72 Simultaneous 2 12 24 48 72
HCT15 +TNFa 0.98 1.03 1.08 1.08 1.75 1.85 1.1 2.4 3.6 5.14 5.3 9.0
+ IL-2 1.01 1.04 1.2 1.3 1.57 1.57 1.0 1.05 1.05 1.2 1.6 2.3
+IFNy 1.1 1.1 1.15 1.23 1.53 1.6 1.08 1.16 1.18 1.8 2.1 2.17
HCT116 +TNFa 1.1 1.15 1.2 1.2 1.65 1.58 1.04 1.13 7.2 14.2 17.3 21.6
+ IL-2 1.04 1.04 1.15 1.25 1.54 1.45 0.96 1.04 1.73 1.86 2.6 2.6
+IFNy 1.07 1.1 1.15 1.2 1.55 1.5 1.0 1.1 1.6 2.4 2.65 2.6
aDMF, The dose-modifying factors were defined as the ratio between the IC50 of the respective anti-cancer drugs without cytokine treatment
(controls) and with cytokine treatments.Cytokine mediated reversal of MDR
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reduction of mdrl expression was detected in all cytokine-
treated cells, this effect was most striking in cells incubated
with TNF. However, the time dependence of the cytokine-
induced decrease in mdrl expression after 48 h was also
observed in cells treated with IL-2 and IFNy. After 72 h of
cytokine treatment, mdrl expression increased again, reaching
a level close to untreated controls.
The influence of cytokine treatment on mdrl mRNA level
was calculated as relative mdrl expression determined as the
ratio of mdrl to ,B-actin expression by semiquantitative
analysis (at least three independent cytokine treatment
experiments). Compared with the untreated control cells of
both lines, the data of the relative mdrl expression confirm
the time dependence of the cytokine-caused decrease in mdrl
expression, with the most convincing effect after 48 h.
P-glycoprotein expression in cytokine-treated cells detected by
MRK16 and C219
Determination of P-glycoprotein expression was performed
with the two monoclonal antibodies, MRK16 and C219.
After incubation with a secondary, fluorescein-conjugated
antibody, the level of P-glycoprotein was measured by
immuno flow cytometry and compared with untreated cells
serving as controls. P-glycoprotein expression determined in
the untreated cells of both lines at all time points remained
unchanged. Untreated colon carcinoma cell lines were
compared concerning their intrinsic P-glycoprotein expres-
sion: FACScan histograms for MRK16, recognising an
extracellular epitope, showed a mean fluorescence per cell
of 141.5 for HCT15 and 41.9 for HCT116 (Figure 2). Thus,
the MRK16-detected P-glycoprotein expression in the more
a
U) c
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Figure 2 P-glycoprotein expression in cytokine-pretreated human
colon carcinoma cells, detected with the monoclonal antibody,
MRK 16. a, HCT 15; b, HCT 116. Fluorescence intensity was
measured with a FACScan flow cytometer as mean fluorescence of
1 x 104 cells. Each value represents the average of triplicate
experiments (s.d. was less than 10%). The cytokine-mediated
time-dependent differences in mean fluorescence were tested for
significance with Student's t-test. -A-, TNF; -0-, IL-2; -U-
IFNy.
resistant HCT15 cells was approximately 3.5 times higher
than in the HCT116 cells (P<0.0004). Results obtained with
the C219 antibody, binding to a cytoplasmic epitope of P-
glycoprotein, demonstrated a similar situation (Figure 3): the
mean fluorescence per cell for HCT15 was 82.4, whereas the
value for HCT116 was 47.8, reflecting an approximately 2-
fold higher P-glycoprotein expression level for HCT15
compared with HCT116 (P<0.008).
To analyse the influence of cytokines on P-glycoprotein
expression, colon carcinoma cells were treated with
100 U ml-' TNF, IL-2 or IFNy for 2, 12, 24, 48 or 72 h.
Cells were then incubated with MRK16 or C219, respectively,
as described in Materials and methods. In general, a time-
dependent reduction of P-glycoprotein expression was
observed in both cell lines after treatment with TNF, IL-2
or IFNy. Results obtained with the two monoclonal
antibodies, MRK16 and C219, were in agreement and
consistent with the data on mdrl mRNA level. The
maximum decrease of P-glycoprotein expression was after
48 h of cytokine treatment, shown for both lines with
MRK16 in Figure 2. In HCT15 cells (Figure 2a), the mean
fluorescence per cell after 48 h TNF treatment was 44.7
compared with untreated controls with 141.5, representing a
significant decrease in P-glycoprotein expression (P<0.0004).
Similar situations were observed with IL-2- or IFNy-treated
HCT15 cells with mean fluorescence values of 46.9 for IL-2
(P<0.0007) and 57.0 for IFNy (P<0.0009). In HCT116 cells
(Figure 2b), the maximum time-dependent reduction of P-
glycoprotein was observed with mean fluorescences per cell of
15.8 for TNF (P<0.0006), 19.9 for IL-2 (P<0.001) and 20.3
for IFNy (P<0.001), compared with untreated control cells
(mean fluorescence 41.9).
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Figure 3 P-glycoprotein expression in cytokine-pretreated human
colon carcinoma cells, detected with the monoclonal antibody,
C219. a, HCT 15; b, HCT 116. Fluorescence intensity was
measured with a FACScan flow cytometer as mean fluorescence
of 1 x 104 cells. Each value represents the average of triplicate
experiments (s.d. was less than 10%). The cytokine-mediated
time-dependent differences in mean fluorescence were tested for
significance with Student's t-test. -A-, TNF; -0- IL-2; -
IFNy.Cytokine mediated reversal of MDR
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Results obtained with the monoclonal antibody C219 are
summarised in Figure 3, confirming the time dependence as
well as the cell type specificity of the cytokine-modulated P-
glycoprotein expression. In HCT15 cells (Figure 3a),
significantly decreased mean fluorescence was measured after
48 h treatment with TNF (17.5; P<0.0003), IL-2 (12.6;
P<0.0002) and IFNy (30.0; P<0.0005), compared with
untreated parental cells (82.4). In the HCT116 line (Figure
3b), cytokine-induced effects after 48 h were determined as a
mean fluorescence per cell of 22.5 for TNF (P<0.002), 27.5
for IL-2 (P<0.005) and 17.8 for IFNy (P<0.0008) with
regard to the controls (47.8).
Doxorubicin accumulation in cytokine-treated cells
To assess mdrl expression on the functional level, accumula-
tion of the fluorescent MDR-associated drug, doxorubicin,
was measured and quantitated by FACScan analysis in both
colon carcinoma lines. Doxorubicin accumulation in un-
treated cells was approximately 7 times lower in the more
resistant HCT15 compared with HCT116 cells, as illustrated
in Figure 4. This is reflected by the mean fluorescence per cell
of 32 observed for HCT15 and 205 for HCT116, as
determined after 3 h doxorubicin incubation.
To examine the influence of cytokines on P-glycoprotein
function, cells were treated with TNF, IL-2 or IFNy for 2,
12, 24, 48 or 72 h. Cytokine-pretreated cells were incubated
with doxorubicin for 3 h and the accumulated fluorescent
drug was measured. An enhancement of doxorubicin
accumulation was determined in all cytokine-pretreated cells
of both lines. The highest drug fluorescence was measured in
cells incubated for 48 h with cytokine. In HCT15, mean
fluorescence per cell following 48 h cytokine treatment was as
follows: 138 for TNF (P<0.0003), 97 for IL-2 (P<0.0004)
and 82 for IFNy (P<0.0005) (control: 32; Figure 4a). Uptake
data obtained for HCT1 16 treated for 48 h were 467 for TNF
(P<0.0009), 347 for IL-2 (P<0.004) and 656 for IFNy
(P<0.0004) (control: 205; Figure 4b).
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Figure 4 Doxorubicin accumulation in cytokine-pretreated
human colon carcinoma cells. a, HCT 15; b, HCT 116.
Fluorescence intensity was measured with a FACScan flow
cytometer as mean fluorescence of 1 x 104 cells. Each value
represents the average of triplicate experiments (s.d. was less than
15%). The cytokine-mediated time-dependent differences in mean
fluorescence were tested for significance with Student's t-test.
-A-, TNF; -0- IL-2; -U- IFNy.
Enhancement of chemosensitivity in cytokine-treated cells
To determine if cytokine pretreatment caused a sensitisation
ofmultidrug-resistant human colon carcinoma cells to MDR-
associated drugs, cells were preincubated with TNF, IL-2 and
IFNy for 2, 12, 24, 48 and 72 h. The following treatments
with anti-cancer drugs were then carried out for 3 days in a
concentration range of 50 to 2000 ng ml-' doxorubicin or
vincristine. Cytotoxicity was expressed as percentage growth
inhibition compared with untreated control cells. Cells only
treated with the appropriate drug or cells simultaneously
treated with cytokine and anti-cancer drug served as
additional controls (Figures 5 and 6).
For all combinations of cytokines and drugs (TNF, IL-2
or IFNy plus doxorubicin, Figure 5 a-c and 6 a-c; TNF,
IL-2 or IFNy plus vincristine, Figure 5 d-f and 6 d-f),
cytotoxicity was enhanced by cytokine pretreatment. In
general, increase in cytotoxicity was time dependent with a
maximum enhancement after cytokine preincubations for 48
and 72 h. Although the cytokine-induced enhancement of
cytotoxicities of the MDR-associated drugs, doxorubicin and
vincristine, were seemingly independent from the cytokine
used, the highest increase was achieved by TNF.
To evaluate the sensitising effects of cytokine pretreat-
ments in the two tumour lines, the IC50 values for
doxorubicin and vincristine were determined for untreated
and cytokine-treated (pretreatment or simultaneous treat-
ment) cells and their ratio was given as dose-modifying
factors (DMFs) (Table I). Thus, after 48 and 72 h ofcytokine
pretreatment, significantly increased cytotoxicities were
observed for all combinations analysed in both cell lines.
For example, in vincristine-treated HCT116 cells, DMFs of
17.3 (48 h) and 21.6 (72 h) were measured for TNF
pretreatment (P<0.00009). In highly resistant vincristine-
treated HCT15 cells, DMFs of 5.3 (48 h) and 9.0 (72 h) were
determined (P<0.0002). In contrast to pretreated cells,
simultaneous incubation of cytokine and anti-cancer drug
did not result in a significant increase of cytotoxicity, either
for doxorubicin or for vincristine.
Discussion
Colorectal cancer is one of the leading causes of cancer
morbidity and mortality in the world (Goldstein et al., 1989).
Although there has been extensive research on a variety of
chemotherapeutic treatment regimens, a decisive success in
increasing survival time ofpatients with colorectal cancer has
yet to be achieved. Since overexpression of mdrl gene in
normal human colorectal tissue, as well as in human
colorectal cancer, has been described frequently (Mizoguchi
et al., 1990; Park et al., 1990; Lai et al., 1991), this intrinsic
or acquired resistance against MDR-associated drugs, like
doxorubicin, vincristine or actinomycin D, might be a reason
for the failure of chemotherapeutic treatments with these
drugs. Thus, colon cancer may be an area in which MDR
reversal strategies may have benefit. The sensitisation of this
tumour type to drugs, which are originally not in favour for
the treatment of colon cancer, might have a therapeutic
impact and could broaden the spectrum of drugs for
chemotherapy of this cancer.
In the present report, the capability of cytokines to
modulate MDR has been investigated in the highly drug-
resistant HCT15 human colon carcinoma cell line and the
HCT116 cell line, which manifests a lesser degree of
multidrug resistance. In this study, cytokine effects as an
approach for reversal of MDR were analysed on the mdrl
mRNA level by RT-PCR, as well as on the P-glycoprotein
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Figure 5 Cytotoxicity of doxorubicin or vincristine in cytokine-pretreated HCT15 colon carcinoma cells. Tumour cells were
preincubated with TNFa (a, d), IL-2 (b, e) or IFNy (c, f) for 2h (@), 12h (O>), 24h (+), 48h (*) or 72h (El) respectively.
Thereafter, cells were incubated with doxorubicin or vincristine at the indicated concentrations for 3 days. Cytotoxicity was
measured in duplicates by the XTT colorimetric assay and expressed as % growth inhibition compared with the untreated tumour
cells. Cells treated only with doxorubicin or vincristine (0); and cells treated simultaneously with cytokines and cytostatics (A)
served as controls. Variations (s.d.) were less than 15% of the total measurements.
level by using the monoclonal antibodies MRK16 and C219
and immuno flow cytometry. Cytokine-modulated P-glyco-
protein function was examined by accumulation assays with
the fluorescent MDR-associated drug, doxorubicin. Cytokine-
influenced MDR phenotypes of both cell lines were
determined by XTT chemosensitivity assays with doxorubicin
and vincristine. The following results were achieved: (1)
cytokines were able to decrease mdrl expression on the
mRNA as well as on the P-glycoprotein level; (2) these effects
were reflected in P-glycoprotein function; (3) cytokines
augment the cytotoxicity of the MDR-associated drugs,
doxorubicin and vincristine; (4) cytokines act in a time-
dependent manner with maximum down-regulation in mdrl
mRNA and P-glycoprotein levels after 48 h treatment; and
finally, (5) cytokines modulate mdrl expression, P-glycopro-
tein function as well as drug sensitivity. These results confirm
and extend our earlier data describing cytokine-mediated
alteration of mdrl expression (Walther and Stein, 1994). In
this study, we give evidence ofdependence on time and on the
cell line's MDR phenotype of these cytokine activities. It is
further shown that cytokines are able to enhance cytotoxicities
of MDR-associated drugs, expressed by reduced IC50 for
doxorubicin and vincristine. The cytokine-mediated sensitisa-
tion ofhuman tumour cells was manifested as a reversal ofthe
MDR phenotypes of both cell lines. Cytokine treatment
caused a decrease ofmdrl expression, as well as the increase of
doxorubicin accumulation and resultant cytotoxicity.
Although our data suggest that cytokine treatment sensitises
cell lines to cheniotherapeutic drugs through a P-glycoprotein-
mediated mechanism, because there is no strict correlation
between relative MDR ranking and relative P-glycoprotein in
colon carcinoma cell lines (Izquierdo et al., 1996), we cannot
rule out the possibility that cytokines are also working in these
cell lines through one or more non-P-glycoprotein-mediated
mechanisms.
Some studies have described effects of externally added
cytokines on MDR phenotypes, but only a few of them
analysed the cytokine-induced modulation of mdrl gene
expression on both the mRNA and P-glycoprotein level
(Salmon et al., 1989; Scala et al., 1991; Evans and Baker,
1992; Walther and Stein, 1994; Kang and Perry, 1994). There
were no alterations found for mdrl expression on mRNA
levels in human drug-sensitive and -resistant leukaemia and
myeloma cell lines 24 h after cytokine treatment (Salmon et
al., 1989). This represents exactly the same incubation time in
which we are also unable to detect significant changes in
HCT15 and HCT116 cells. Studies investigating the effects
caused by IFNa include one report which described increased
mdrl expression on RNA and protein level within treatment
intervals of up to 24 h in the Chinese hamster ovary cell line
Chr C5 (Kang and Perry, 1994), and one report showing
unchanged P-glycoprotein expression in LoVo colon carci-
noma cells (Scala et al., 1991). For a panel of 21 known or
newly discovered cytokines, including TNF, IL-2, IFNo and
IFNy, unaffected P-glycoprotein levels were observed with
cytokine treatments of 2 h, except for the cytokine,
leukoregulin, which caused decreased mdrl expression
(Evans and Baker, 1992). Elevated accumulation of fluor-
escent P-glycoprotein substrates, like rhodamine 123 or
doxorubicin, after cytokine treatment have been reported
for the cytokines TNF, IFNa, IL-la and leukoregulin (Scala
et al., 1991; Evans and Baker, 1992; Valenti et al., 1993;
Borsellino et al., 1994), reflecting a sensitisation of the MDR
phenotype in these cells. Interestingly, in contrast to the
contradictory results described for cytokine effects on mdrl
expression, investigations are in rather good agreement
concerning cytokine-induced P-glycoprotein function. The
greatest agreement concerning cytokine-altered MDR pheno-
types was reported for TNF, IFNa, IFNy, IL-2 and IL-la
and leukoregulin, based on chemosensitivity experiments with
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Figure 6 Cytotoxicity of doxorubicin or vincristine in cytokine-pretreated HCT1 16 colon carcinoma cells. Tumour cells were
preincubated with TNFa (a, d), IL-2 (b, e) or IFN-y (c, f) for 2h (0), 12h (O), 24h (+), 48 h (*) or 72h (O) respectively.
Thereafter, cells were incubated with doxorubicin or vincristine at the indicated concentrations for 3 days. Cytotoxicity was
measured in duplicates by the XTT colorimetric assay and expressed as % growth inhibition compared with the untreated tumour
cells. Cells treated only with doxorubicin or vincristine (0); and cells treated simultaneously with cytokines and cytostatics (A)
served as controls. Variations (s.d.) were less than 15% of the total measurements.
the MDR-associated cytotoxic drugs like doxorubicin,
vincristine or actinomycin D (Scala et al., 1991; Evans and
Baker, 1992; Kikuchi et al., 1992; Monti et al., 1993; Valenti
et al., 1993; Walther and Stein, 1994; Borsellino et al., 1994;
Kamikaseda et al., 1994). Moreover, MDR reversal results
have been described for combination of cytokines (e.g. IFNa)
with agents that inhibit P-glycoprotein function, like
monoclonal antibodies, such as MRK16 (Fogler et al.,
1995), as well as for a combination with verapamil (Kang
and Perry, 1994).
Interestingly, chemosensitivity assays have shown that
cytokines of different origins and modes of action cause the
same effect: they are capable of MDR reversal. In this-study
we describe the modulatory effects on mdrl expression and
function as well as on cytotoxicities of MDR-related drugs
caused by TNF, IL-2, and IFNy. The finding that these
cytokines exert the same effect could be explained by the well-
accepted fact that cytokines act with redundancy and
pleiotropy in very different cell types (for review see
Kroemer et al., 1993). Another possible mechanism of
action of these three cytokines could be the induction of
expression of at least one major active cytokine which, in
turn, may be responsible for the modulation of mdrl
expression. This hypothesis is supported by the findings of
cytokine cascades (Kroemer et al., 1993). It is well known
that, e.g. TNF expression is inducible by IL-2 or IFNy
(Sidhu and Bollon, 1993), and it will be of great interest to
determine whether such a mechanism of cytokine induction
takes place in treated tumour cells.
The potential of cytokines for MDR reversal, especially in
highly resistant tumour cells, makes cytokine pretreatment an
attractive approach for improved chemotherapy of these
tumours. The present results suggest additional possibilities
for more sophisticated combination therapies involving
cytokines and MDR-related drugs.
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